In vitro, B16 cells exposed to IL‐6 and its soluble IL‐6 receptor or IL6RIL6 chimeric protein undergo transdifferentiation from melanoma to a glial cell phenotype.[22, 23, 24] In vivo experiments using B16 cells expressing IL‐6 and its soluble receptor have shown weak subcutaneous tumorigenicity and lung metastasis ability, as well as long survival.[25]. The gene discussed is IL6; the disease is melanoma.